Azitra, Inc. Takes Positive Steps Toward NYSE Compliance with New Listing Plan

Azitra, Inc. Moves Forward with NYSE Compliance Strategy

On December 17, 2025, Azitra, Inc., a biopharmaceutical company listed on NYSE American under the ticker AZTR, announced a significant milestone in its journey toward compliance with exchange requirements. The company has received an acceptance notice from NYSE American concerning its compliance plan, aimed at rectifying previous financial discrepancies related to its stockholder equity.

Background on Compliance Issues

In October 2025, Azitra was notified by NYSE American that it was not meeting the minimum stockholder equity threshold of $4 million, as outlined in Section 1003(a)(ii) of the NYSE American Company Guide. This requirement is particularly crucial for companies like Azitra, which must maintain a solid financial standing to avoid delisting. The Exchange's concerns arose due to the company's reported losses over the previous fiscal years, raising alarm about its ongoing solvency and stability in the market.

To address these issues, the exchange placed a deadline for compliance by April 1, 2027. If Azitra fails to meet this deadline or show progress following the outlined plan, it faces potential delisting from the NYSE American, an outcome that could severely impact its operations and stockholder interest.

Steps Forward

In response to the critical situation, Azitra's management has formulated a comprehensive plan to restore compliance and has pledged to explore various funding opportunities to bolster its financial base. This proactive approach highlights the company's commitment to meeting regulatory standards and enhances investor confidence as they navigate crucial operational milestones.

The acceptance of Azitra's plan means that the company will remain listed on NYSE American during the compliance period and will undergo regular reviews, including quarterly monitoring to ensure adherence to the stipulated conditions. Despite the ongoing challenges, the immediate effect on the company's stock trading has been stabilizing, allowing it to maintain active investor engagement.

Azitra's Core Business and Innovation

Founded with a mission to develop innovative therapies, Azitra focuses on precision dermatology. Its leading product, ATR-12, utilizes a specially engineered strain of S. epidermidis aimed at treating Netherton syndrome—a rare skin disorder without existing treatment options. This disease can have life-threatening implications for many infants, making the development of effective therapies not only a business venture but a humanitarian necessity.

In addition to ATR-12, Azitra is advancing its ATR-04 program, which targets EGFR inhibitor-associated rash. The FDA has bestowed Fast Track designation upon this product due to its availability for the approximately 150,000 patients dealing with this condition in the United States alone. Utilizing a proprietary platform that combines engineered proteins with advanced artificial intelligence capabilities enables Azitra to potentially expand its portfolio of treatment options significantly.

Looking Ahead

As Azitra navigates the challenges posed by compliance and continues to pursue innovative dermatological solutions, the company is also keenly aware of the risks inherent in the biopharmaceutical sector. Recent press statements have underscored that while management remains confident in its plans, various external factors might impact progress, including funding avenues and competition.

In closing, Azitra, Inc. stands at a pivotal point, balancing the demands of regulatory compliance with its commitment to groundbreaking therapeutic development. As the company charts its course for the future, stakeholders will be closely monitoring how effectively it manages these dual objectives within the competitive landscape of biopharmaceutical development.

For more details, visit Azitra's official website at azitrainc.com.